Selborne Biological Services — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Selborne Biological Services is a private, early-revenue stage contract research organization (CRO) specializing in antibody-focused research services. The company provides critical outsourced R&D capabilities, such as assay development and preclinical testing, to biotech companies that lack full in-house infrastructure. Positioned in Cambridge, UK, it benefits from proximity to a dense cluster of innovative life sciences companies. Its business model is based on fee-for-service contracts, offering a capital-light path to growth by serving the burgeoning pipeline of antibody-based therapeutics.

Antibodies

Technology Platform

Integrated suite of antibody-focused laboratory services including assay development, compound screening, and preclinical testing capabilities.

Opportunities

Strong growth in the antibody therapeutics market and increased biopharma R&D outsourcing create sustained demand for specialized CRO services.

Its location in the Cambridge biotech cluster provides direct access to a high concentration of potential clients, from startups to established companies.

Risk Factors

Faces intense competition from both large global CROs and other niche providers.

Revenue is vulnerable to downturns in biotech funding, as clients may reduce outsourced R&D spending.

Operational success is entirely dependent on maintaining an impeccable reputation for data quality and reliability.

Competitive Landscape

Competes within the fragmented preclinical CRO market. Key competitors include large players like Labcorp, Charles River, and Eurofins, as well as numerous small, specialized CROs. Differentiation is achieved through deep antibody expertise, personalized service, and agility, rather than scale.

More companies in United Kingdom →